With the growing use of Stelara® biosimilars, we’re expanding coverage to include additional options for our commercial group and individual members to ensure they have access to needed treatment.
Effective immediately, Steqeyma® and Starjemza™ are covered under the pharmacy benefit at Tier 4 with prior authorization requirements and under the medical drug benefit, with prior authorization and site of service requirements.
In addition to Steqeyma and Starjemza, we offer the same coverage for Selarsdi® and Yesintek®, all of which are biosimilars of Stelara and have been granted interchangeable status* by the Food and Drug Administration (FDA). *Rules for interchangeable status vary by state. If your patient is filling their prescription at a pharmacy outside of Michigan, a new prescription for any of the above biosimilars may be required.
What do they treat?
Steqeyma and Starjemza are interchangeable Stelara biosimilars used to treat a variety of autoimmune conditions, including certain types of plaque psoriasis, active psoriatic arthritis, Crohn’s disease and ulcerative colitis.